Skip to main content

Galapagos NV (GLPG)

NASDAQ: GLPG · Delayed Price · USD
51.05
-0.89 (-1.71%)
Pre-market:Oct 22, 2021 7:43 AM EDT
51.94
0.33 (0.64%)
At close: Oct 21, 4:00 PM
Market Cap3.37B
Revenue (ttm)646.66M
Net Income (ttm)-372.48M
Shares Out65.53M
EPS (ttm)-3.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume175,460
Open51.32
Previous Close51.61
Day's Range51.15 - 52.03
52-Week Range48.66 - 130.26
Beta0.37
AnalystsHold
Price Target115.20 (+121.8%)
Est. Earnings DateNov 4, 2021

About GLPG

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690...

IndustryBiotechnology
IPO DateMay 6, 2005
CEOOnno van de Stolpe
Employees1,397
Stock ExchangeNASDAQ
Ticker SymbolGLPG
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 10 analysts, the average rating for Galapagos stock is "Hold." The 12-month stock price forecast is 115.20, which is an increase of 121.79% from the latest price.

Price Target
$115.20
(121.79% upside)
Analyst Consensus: Hold

News

Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study

Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.

2 weeks ago - Zacks Investment Research

Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients

Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC).  The analyses showed clinical benefi...

2 weeks ago - Benzinga

Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 20...

Mechelen, Belgium ; 4 October 2021, 22.01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announce d results of two post-hoc analyses from the SELECTION and SELECTION LTE studies , which are part of ...

2 weeks ago - GlobeNewsWire

Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease

Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in patients with Crohn's Disease (CD). The DIVERS...

2 weeks ago - Benzinga

Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn's Disease

Mechelen, Belgium; 4 October  2021, 07.01  CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced randomization of the last patient in to the multi-cent er , global DIVERSITY Phase 3 study . The st...

2 weeks ago - GlobeNewsWire

Galapagos increases share capital through subscription right exercises

Mechelen, Belgium; 20 September 2021 , 22. 01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

1 month ago - GlobeNewsWire

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO S...

Mechelen, Belgium ; 17 September 2021 ; 13.15 CET ; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP...

1 month ago - GlobeNewsWire

Galapagos Says New CEO Will Have Strong Science Background

When any team underperforms, it's usually the manager or coach who gets the axe. The same often holds true in the corporate world.

1 month ago - GuruFocus

Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks

After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership. He will stay in his role until a succ...

1 month ago - Benzinga

Galapagos announces planned retirement of CEO

Galapagos announces planned retirement of CEO

1 month ago - GlobeNewsWire

Galapagos reports H1 financial results with refocused pipeline and operational progress

Webcast presentation tomorrow , 6 August 202 1 , at 14.00 CET / 8 AM ET, www.glpg.com , +32 2 793 38 47 , code 8245 817

2 months ago - GlobeNewsWire

Here's Why Galapagos Stock Is Falling Today

The company's new salt-inducable kinase inhibitor program is getting off to a rocky start.

3 months ago - The Motley Fool

Galapagos (GLPG) Falls on Inflammatory Study Data Readout

Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

3 months ago - Zacks Investment Research

Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage Study

Galapagos NV (NASDAQ: GLPG) reported topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients. At Week 4, four out of 10 patients in the high dose group...

3 months ago - Benzinga

Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Pa...

Galapagos NV (NASDAQ: GLPG) reports topline results from three studies evaluating GLPG3970, a SIK inhibitor, in psoriasis, ulcerative colitis (UC), and rheumatoid arthritis (RA).  26-patient CALOSOMA ps...

3 months ago - Benzinga

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

Mechelen, Belgium; 1 4 July 2021; 2 2 . 01 CET ; regulated information - Galapagos NV (Euronext & Nasda q : GLPG) reports positive topline results with tyrosine kinase 2 ( TYK2 ) inhibitor GLPG3667 in a...

3 months ago - GlobeNewsWire

Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

Mechelen, Belgium; 14 July 2021; 2 2 . 01 CET ; regulated information – Galapagos NV (Euronext & Nasda q : GLPG) reports topline results with GLPG3970 in three pati e nt studies . GLPG3970 , the first p...

3 months ago - GlobeNewsWire

Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotini...

New post-hoc analys es of data from SELECTION P hase 3 program presented at European Crohn's and Colitis Organisation (ECCO) virtual congress

3 months ago - GlobeNewsWire

Galapagos announces departure of CSO Piet Wigerinck later this year

Mechelen, Belgium; 22 June 202 1 , 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces the departure of Dr. Piet Wigerinck later this year .

3 months ago - GlobeNewsWire

Galapagos increases share capital through subscription right exercises

Mechelen , Belgium; 7 June 2021 , 22. 01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

4 months ago - GlobeNewsWire

Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

Mechelen, Belgium, 27 May 2021, 22 :01 CET, – Galapagos NV (Euronex t & Nasdaq: GLPG) today announced that 15 abstracts , including scientific updates, and data providing further understanding on the pr...

4 months ago - GlobeNewsWire

Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effec...

Study uses mobile device technology to support capture of patient - reported outcomes during early and ongoing use of stud y treatment amongst patients with rheumatoid arthritis

5 months ago - GlobeNewsWire

Galapagos Drops Early Metabolic & Osteoarthritis Programs, Reorganizes R&D Efforts

Galapagos NV (NASDAQ: GLPG) is chopping its pipeline to conserve cash while its business development team pursues a mission to find a “transformative” deal for the company. The company is ditching its I...

5 months ago - Benzinga

Galapagos creates new subscription right plans

Mechelen, Belgium ; 30 April 2021 , 22.01 CET; regulated information – – Galapagos   NV (Euronext & NASDAQ : GLPG) announced today that its supervisory b oard created 2, 7 36,250 subscription rights und...

5 months ago - GlobeNewsWire

e-therapeutics reaches two key milestones in Galapagos collaboration

e-therapeutics PLC (LON:ETX) has reached two key milestones in its collaboration with Galapagos NV, triggering two payments to the company. The two operational and success-based milestones were defined ...

5 months ago - Proactive Investors